178 related articles for article (PubMed ID: 7483725)
1. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
3. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
[TBL] [Abstract][Full Text] [Related]
4. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
5. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression.
Hadasová E; Franke G; Zschiesche M; Cesková E; Zelenková O; Siegmund W
Br J Clin Pharmacol; 1996 May; 41(5):428-31. PubMed ID: 8735687
[TBL] [Abstract][Full Text] [Related]
7. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
9. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine.
Hermann R; Borlak J; Munzel U; Niebch G; Fuhr U; Maus J; Erb K
Pharmacogenomics J; 2006; 6(3):211-9. PubMed ID: 16402080
[TBL] [Abstract][Full Text] [Related]
10. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine hydroxylation in a Polish population.
Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
[TBL] [Abstract][Full Text] [Related]
12. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
Broly F; Meyer UA
Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine oxidation in Parkinson's disease.
Kallio J; Marttila RJ; Rinne UK; Sonninen V; Syvälahti E
Acta Neurol Scand; 1991 Mar; 83(3):194-7. PubMed ID: 2031454
[TBL] [Abstract][Full Text] [Related]
14. [Acetylation polymorphism in lung cancer].
Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C
Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
[No Abstract] [Full Text] [Related]
16. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
18. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
19. [Isoniazid acetylation in Gilbert's syndrome].
Pereira-Filho RA; Sevá-Pereira A; de Magalhães AF
Arq Gastroenterol; 1985; 22(4):172-5. PubMed ID: 3837656
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
